A new study by researchers at The University of Texas MD Anderson Cancer Center has identified genetic factors that determine ...

ROCHESTER — Mayo Clinic and GE HealthCare will conduct research on an emerging treatment for prostate cancer and how that treatment can become more personalized to each patient, the two ...

Federal officials may remove warnings on testosterone therapy drugs about heart and prostate risks, which could expand access ...

The partnership will evaluate whether imaging- and biomarker-informed insights can support a more personalised approach to ...

Federal health officials are quietly moving to overhaul the fine print on testosterone replacement therapy, a shift that ...

In the United States, prostate cancer is a leading cause of cancer-related disease and death in men. About half of prostate ...

Tiny silica nanoparticles engineered to seek out prostate cancer caused tumor cells to self-destruct and supercharged the ...

The US government wants testosterone replacement therapy labels updated to reflect newer research on heart health and prostate cancer, but doctors stress that treatment should still be reserved for ...

The treatment, called Pasritamig, teaches the immune system's T cells to target and attack cancer cells in the prostate.

An enhanced telehealth model demonstrates feasibility and high clinician and patient acceptability for prostate cancer management.

The study is aimed at advancing personalized cancer treatment by exploring a personalized approach to radioligand therapy.

NeoGenomics launched PTEN IHC CDx, the first IHC companion diagnostic test approved by the U.S. FDA for patients with ...